Vertex Pharmaceuticals VRTX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Product revenues, net by Product | |||||
| ALYFTREK | $837.8M— | $0— | $0— | —— | |
| CASGEVY | $115.8M+1,058% | $10M— | —— | —— | |
| JOURNAVX | $59.6M— | $0— | —— | —— | |
| Other CF product revenues | $804.6M+3.0% | $781.5M— | —— | $1.24B— | |
| TRIKAFTA/KAFTRIO | $10.31B+0.7% | $10.24B+14.5% | $8.94B+16.4% | $7.69B+34.9% | |
| Cost of Sales by Product | |||||
| Product revenues, net | $601.5M+16.5% | $516.3M+47.9% | $349.2M+34.0% | $260.5M— | |
| Royalty | $1.05B+3.5% | $1.01B+11.1% | $913M+11.4% | $819.8M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vertex Pharmaceuticals break its business down?
- Vertex Pharmaceuticals (VRTX) reports product revenues, net by product across 5 parts — ALYFTREK, CASGEVY, JOURNAVX, Other CF product revenues and TRIKAFTA/KAFTRIO. Each is extracted from the segment footnotes and tracked over time.
- Where does Vertex Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vertex Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
